The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Safety and efficacy of a CXCR 2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial
Abstract
Summary: Background: Increased numbers of neutrophils are reported in the airways of patients with severe asthma. It is not clear if they contribute to the lack of control and severity. There are currently no strategies to investigate this by decreasing neutrophil numbers in the airways. Objective: To investigate the safety and efficacy of SCH 527123, a selective CXCR 2 receptor antagonist, in patients with severe asthma and increased number of neutrophils in sputum. Methods: In a randomized, double‐blind, parallel study, patients with severe asthma and sputum total cell count < 10 × 10 6/g and neutrophils > 40% were randomized to SCH 527123, 30 mg daily PO (n = 22) or placebo (n = 12) for 4 weeks. Primary end‐points were safety and change in sputum and blood neutrophil counts. Secondary end‐points were change in asthma control questionnaire (ACQ) score, minor and major exacerbations, spirometry and sputum neutrophil activation markers. Results: The SCH 527123 caused a mean reduction of 36.3% in sputum neutrophil percentage compared to a 6.7% increase in the placebo arm (P = 0.03). The mean absolute neutrophil count in blood was reduced by 14% at the end of 4 weeks, but recovered by the 5th week. There were no differences in the overall rates of adverse events among the groups. There were fewer mild exacerbations (1.3 vs. 2.25, P = 0.05) and a trend towards improvement in the ACQ score (mean difference between groups of 0.42 points, P = 0.053). No statistically significant changes were observed in forced expiratory volume in 1 s (FEV 1), sputum myeloperoxidase, IL 8 or elastase. Conclusions: The SCH527123 is safe and reduces sputum neutrophils in patients with severe asthma. Clinical Relevance: This new treatment provides an opportunity to investigate the role of neutrophils in severe asthma with potential clinical benefits. Larger studies of longer duration are needed to evaluate the impact on other outcomes of asthma including exacerbations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Self-citationWENZEL, S. E., SCHWARTZ, L. B., LANGMACK, E. L., HALLIDAY, J. L., TRUDEAU, J. B., GIBBS, R. L., & CHU, H. W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9812110 · Cited by 1,235
Juniper, E. F., Bousquet, J., Abetz, L., & Bateman, E. D. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2005.08.012 · Cited by 998
Juniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., Calhoun, W. J., Castro, M., Chung, K. F., Clark, M. P., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.11.639 · Cited by 929
Neutrophilic Inflammation in Severe Persistent Asthma
JATAKANON, A., UASUF, C., MAZIAK, W., LIM, S., CHUNG, K. F., & BARNES, P. J. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.5.9806170 · Cited by 851
The ENFUMOSA Study Group (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00261903 · Cited by 759
Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation
Fahya, B., Kimb, K. W., Liub, J., & Bousheya, B. (1995) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(95)70128-1 · Cited by 678
Cited by
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationAfter asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Neutrophil migration in infection and wound repair: going forward in reverse
de Oliveira, S., Rosowski, E. E., & Huttenlocher, A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.49 · Cited by 1,058
Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury
Kruger, P., Saffarzadeh, M., Weber, A. N. R., Rieber, N., Radsak, M., von Bernuth, H., Benarafa, C., Roos, D., Skokowa, J., & Hartl, D. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004651 · Cited by 657
The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
Russo, R. C., Garcia, C. C., Teixeira, M. M., & Amaral, F. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.894886 · Cited by 647
Metadata
- Authors
- Nair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F. E., O'Byrne, P. M., Stryszak, P., Gann, L., Sadeh, J., Chanez, P., & on behalf of the study investigators
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2012-06-15
- Volume
- 42
- Issue
- 7
- Pages
- 1097-1103
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W1992347215
- Cited by
- 333
- References
- 27
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of a CXCR 2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial. https://app.cochat.ai/papers/10.1111/j.1365-2222.2012.04014.x
- The paper
- Nair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F. E., O'Byrne, P. M., Stryszak, P., Gann, L., Sadeh, J., Chanez, P., & on behalf of the study investigators. (2012). Safety and efficacy of a CXCR 2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2012.04014.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.